StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)
by Teresa Graham · The Cerbat GemEquities researchers at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research note issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Down 10.5 %
AKTX opened at $2.64 on Wednesday. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $4.40. The company has a 50 day simple moving average of $3.36 and a two-hundred day simple moving average of $2.67.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Recommended Stories
- Five stocks we like better than Akari Therapeutics
- Manufacturing Stocks Investing
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Bank Stocks – Best Bank Stocks to Invest In
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Compound Interest and Why It Matters When Investing
- 3 Small-Cap Stocks Ready to Deliver Significant Growth